Precision Immunotherapy for Pediatric Medulloblastoma: Integrating Tumor Immune Microenvironment, Molecular Heterogeneity, and Cellular Therapy

Medulloblastoma (MB) is the most common malignant pediatric brain tumor and remains a major cause of cancer-related morbidity and mortality in children. Although multimodal therapies have significantly improved survival for many patients, children with high-risk, metastatic, or recurrent MB continue to face limited therapeutic options and severe treatment-related complications. Immunotherapy has emerged as a promising strategy. However, clinical responses to conventional immune-based approaches, particularly immune checkpoint blockade, have been modest due to the low immunogenicity, immunosuppressive tumor immune microenvironment (TIME), and substantial molecular heterogeneity of MB. Recent advances in single-cell sequencing, spatial profiling, and molecular classification have revealed that MB consists of distinct biological entities with unique immune landscapes and therapeutic vulnerabilities. These findings have shifted the field from nonspecific immune activation toward precision-guided immunotherapeutic strategies. Several cellular therapies have subsequently been investigated, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR)-engineered T cells, and gamma delta (γδ) T-cell therapies. These approaches have shown encouraging activity in preclinical models; early clinical studies of CAR-T cells support the feasibility of locoregional delivery in pediatric central nervous system (CNS) tumors, although objective responses remain limited and MB-specific efficacy is unestablished. γδ T-cell and TCR-engineered approaches remain preclinical in MB. However, challenges including antigen heterogeneity, immune escape, limited immune-cell trafficking across the central nervous system barriers, and tumor microenvironment-mediated resistance remain major obstacles. This paper summarizes the current understanding of the MB immune microenvironment. It also discusses recent advances in immunotherapeutic strategies, particularly precision cellular therapies. Future strategies involve multi-omics profiling, cellular engineering, and adjustments to the tumor microenvironment. Individualized immunotherapy guided by tumor molecular identity and the immune ecosystem may offer a new approach to improving outcomes in children with high-risk MB.

Authors

Institutions

Publication Details

Journal
Biomolecules
Published
2026-11-17
DOI
https://doi.org/10.3390/biom16111672
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Precision Immunotherapy for Pediatric Medulloblastoma: Integrating Tumor Immune Microenvironment, Molecular Heterogeneity, and Cellular Therapy

Xinling Zhang, 杜来玲, Xiaoping Li, Yujie Wang et al.
3 links
Biomolecules
Glioma Diagnosis and Treatment
article

Precision Immunotherapy for Pediatric Medulloblastoma: Integrating Tumor Immune Microenvironment, Molecular Heterogeneity, and Cellular Therapy

Xinling Zhang, 杜来玲, Xiaoping Li, Yujie Wang, Kewei Tian, Lening Chen, Yuchang Huang
article en

Abstract

Medulloblastoma (MB) is the most common malignant pediatric brain tumor and remains a major cause of cancer-related morbidity and mortality in children. Although multimodal therapies have significantly improved survival for many patients, children with high-risk, metastatic, or recurrent MB continue to face limited therapeutic options and severe treatment-related complications. Immunotherapy has emerged as a promising strategy. However, clinical responses to conventional immune-based approaches, particularly immune checkpoint blockade, have been modest due to the low immunogenicity, immunosuppressive tumor immune microenvironment (TIME), and substantial molecular heterogeneity of MB. Recent advances in single-cell sequencing, spatial profiling, and molecular classification have revealed that MB consists of distinct biological entities with unique immune landscapes and therapeutic vulnerabilities. These findings have shifted the field from nonspecific immune activation toward precision-guided immunotherapeutic strategies. Several cellular therapies have subsequently been investigated, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR)-engineered T cells, and gamma delta (γδ) T-cell therapies. These approaches have shown encouraging activity in preclinical models; early clinical studies of CAR-T cells support the feasibility of locoregional delivery in pediatric central nervous system (CNS) tumors, although objective responses remain limited and MB-specific efficacy is unestablished. γδ T-cell and TCR-engineered approaches remain preclinical in MB. However, challenges including antigen heterogeneity, immune escape, limited immune-cell trafficking across the central nervous system barriers, and tumor microenvironment-mediated resistance remain major obstacles. This paper summarizes the current understanding of the MB immune microenvironment. It also discusses recent advances in immunotherapeutic strategies, particularly precision cellular therapies. Future strategies involve multi-omics profiling, cellular engineering, and adjustments to the tumor microenvironment. Individualized immunotherapy guided by tumor molecular identity and the immune ecosystem may offer a new approach to improving outcomes in children with high-risk MB.

BiomoleculesVol. 16(11)
Zhejiang Shuren University (CN)
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon